TY - JOUR

T1 - Metabonomic investigation of human Schistosoma mansoni infection

AU - Balog, Crina I.A.

AU - Meissner, Axel

AU - Göraler, Sibel

AU - Bladergroen, Marco R.

AU - Vennervald, Birgitte J

AU - Mayboroda, Oleg A.

AU - Deelder, André M.

PY - 2011

Y1 - 2011

N2 - Schistosomiasis is a parasitic infection that is endemic in many developing countries in the tropics and subtropics afflicting more than 207 million people primarily in rural areas. After malaria, it is the second most important parasitic infection in terms of socio-economic and public health. Investigation of the host-parasite interaction at the molecular level and identification of biomarkers of infection and infection-related morbidity would be of value for improved strategies for treatment and morbidity control. To this end, we conducted a nuclear magnetic resonance (NMR) based metabonomics study involving a well-characterized cohort of 447 individuals from a rural area in Uganda near Lake Victoria with a high prevalence of Schistosoma mansoni, a species predominantly occurring in Africa including Madagascar and parts of South America. Cohort samples were collected from individuals at five time-points, before and after (one or two times) chemotherapy with praziquantel (PZQ). Using supervised multivariate statistical analysis of the recorded one-dimensional (1D) NMR spectra, we were able to discriminate infected from uninfected individuals in two age groups (children and adults) based on differences in their urinary profiles. The potential molecular markers of S. mansoni infection were found to be primarily linked to changes in gut microflora, energy metabolism and liver function. These findings are in agreement with data from earlier studies on S. mansoni infection in experimental animals and thus provide corroborating evidence for the existence of metabolic response specific for this infection.

AB - Schistosomiasis is a parasitic infection that is endemic in many developing countries in the tropics and subtropics afflicting more than 207 million people primarily in rural areas. After malaria, it is the second most important parasitic infection in terms of socio-economic and public health. Investigation of the host-parasite interaction at the molecular level and identification of biomarkers of infection and infection-related morbidity would be of value for improved strategies for treatment and morbidity control. To this end, we conducted a nuclear magnetic resonance (NMR) based metabonomics study involving a well-characterized cohort of 447 individuals from a rural area in Uganda near Lake Victoria with a high prevalence of Schistosoma mansoni, a species predominantly occurring in Africa including Madagascar and parts of South America. Cohort samples were collected from individuals at five time-points, before and after (one or two times) chemotherapy with praziquantel (PZQ). Using supervised multivariate statistical analysis of the recorded one-dimensional (1D) NMR spectra, we were able to discriminate infected from uninfected individuals in two age groups (children and adults) based on differences in their urinary profiles. The potential molecular markers of S. mansoni infection were found to be primarily linked to changes in gut microflora, energy metabolism and liver function. These findings are in agreement with data from earlier studies on S. mansoni infection in experimental animals and thus provide corroborating evidence for the existence of metabolic response specific for this infection.

KW - Adolescent

KW - Adult

KW - Aged

KW - Animals

KW - Anthelmintics

KW - Biological Markers

KW - Child

KW - Cohort Studies

KW - Feces

KW - Female

KW - Host-Parasite Interactions

KW - Humans

KW - Magnetic Resonance Spectroscopy

KW - Male

KW - Metabolomics

KW - Middle Aged

KW - Multivariate Analysis

KW - Praziquantel

KW - Schistosoma mansoni

KW - Schistosomiasis mansoni

KW - Time Factors

KW - Uganda

KW - Young Adult

U2 - 10.1039/c0mb00262c

DO - 10.1039/c0mb00262c

M3 - Journal article

C2 - 21336380

VL - 7

SP - 1473

EP - 1480

JO - Molecular BioSystems

JF - Molecular BioSystems

SN - 1742-206X

IS - 5

ER -